ASTRAZEN - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.8
| Stock Code | ASTRAZEN | Market Cap | 21,556 Cr. | Current Price | 8,609 ₹ | High / Low | 10,691 ₹ |
| Stock P/E | 93.2 | Book Value | 320 ₹ | Dividend Yield | 0.37 % | ROCE | 33.4 % |
| ROE | 23.6 % | Face Value | 2.00 ₹ | DMA 50 | 8,691 ₹ | DMA 200 | 8,637 ₹ |
| Chg in FII Hold | -0.03 % | Chg in DII Hold | 0.29 % | PAT Qtr | 58.1 Cr. | PAT Prev Qtr | 56.1 Cr. |
| RSI | 55.8 | MACD | -29.9 | Volume | 6,028 | Avg Vol 1Wk | 4,846 |
| Low price | 6,502 ₹ | High price | 10,691 ₹ | PEG Ratio | 2.16 | Debt to equity | 0.04 |
| 52w Index | 50.3 % | Qtr Profit Var | 51.3 % | EPS | 79.7 ₹ | Industry PE | 29.1 |
📊 The stock ASTRAZEN shows moderate potential for swing trading. Current price (₹8,609) is near its 50 DMA (₹8,691) and 200 DMA (₹8,637), suggesting consolidation. RSI at 55.8 indicates neutral momentum, while MACD (-29.9) shows mild bearishness. Given the high P/E (93.2 vs industry 29.1), valuations are stretched, but strong ROCE (33.4%) and ROE (23.6%) support fundamentals.
💡 Optimal Entry Price: Around ₹8,400–8,500, closer to support levels near 200 DMA.
💡 Exit Strategy: If already holding, consider booking profits near ₹9,200–9,400, or exit if price falls below ₹8,300 with volume confirmation.
Positive
- Strong ROCE (33.4%) and ROE (23.6%) indicate efficient capital use.
- Low debt-to-equity ratio (0.04) ensures financial stability.
- Quarterly profit growth (51.3%) shows improving performance.
- Volume above average suggests active trading interest.
Limitation
- Extremely high P/E (93.2) compared to industry average (29.1).
- Dividend yield is very low (0.37%).
- MACD negative, showing weak short-term momentum.
- FII holding slightly reduced (-0.03%).
Company Negative News
- No major negative news reported, but valuation concerns persist.
Company Positive News
- Consistent profit growth with PAT rising from ₹56.1 Cr. to ₹58.1 Cr.
- DII holdings increased (+0.29%), showing domestic institutional confidence.
Industry
- Pharma sector trading at PE ~29.1, much lower than ASTRAZEN’s valuation.
- Sector outlook remains stable with defensive demand characteristics.
Conclusion
⚖️ ASTRAZEN is fundamentally strong but overvalued relative to peers. It can be considered for swing trading with cautious entry near ₹8,400–8,500 and profit booking around ₹9,200–9,400. Risk management is essential due to stretched valuations and neutral technical indicators.